Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fibrin Fibrinogen Degradation Products | 1 | 2025 | 13 | 0.890 |
Why?
|
| C-Reactive Protein | 1 | 2025 | 167 | 0.820 |
Why?
|
| Monocytes | 1 | 2023 | 277 | 0.670 |
Why?
|
| Shock, Septic | 1 | 2019 | 20 | 0.620 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 40 | 0.610 |
Why?
|
| Hospital Mortality | 2 | 2025 | 210 | 0.350 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3156 | 0.240 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2544 | 0.230 |
Why?
|
| Professional-Family Relations | 1 | 2025 | 11 | 0.230 |
Why?
|
| Internal Medicine | 1 | 2025 | 32 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2025 | 17 | 0.220 |
Why?
|
| Respiratory Insufficiency | 1 | 2025 | 15 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2024 | 247 | 0.220 |
Why?
|
| Humans | 12 | 2025 | 43102 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 1 | 2024 | 38 | 0.200 |
Why?
|
| Internship and Residency | 1 | 2025 | 146 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 133 | 0.200 |
Why?
|
| Aged | 3 | 2025 | 8214 | 0.200 |
Why?
|
| Communication | 1 | 2025 | 210 | 0.200 |
Why?
|
| RNA, Small Interfering | 1 | 2025 | 436 | 0.200 |
Why?
|
| Vaccination | 1 | 2025 | 355 | 0.190 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 3 | 0.190 |
Why?
|
| Pulmonary Surfactants | 1 | 2002 | 33 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2002 | 63 | 0.170 |
Why?
|
| Hawaii | 2 | 2025 | 2011 | 0.170 |
Why?
|
| Middle Aged | 3 | 2025 | 12222 | 0.160 |
Why?
|
| Dobutamine | 1 | 2019 | 7 | 0.160 |
Why?
|
| Milrinone | 1 | 2019 | 5 | 0.160 |
Why?
|
| Epinephrine | 1 | 2019 | 36 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 495 | 0.150 |
Why?
|
| Pseudolymphoma | 1 | 2019 | 5 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2019 | 10 | 0.150 |
Why?
|
| Myocarditis | 1 | 2019 | 24 | 0.150 |
Why?
|
| Cytokines | 1 | 2023 | 678 | 0.150 |
Why?
|
| Male | 5 | 2025 | 23409 | 0.150 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 2853 | 0.140 |
Why?
|
| Female | 5 | 2025 | 24698 | 0.140 |
Why?
|
| Young Adult | 1 | 2025 | 5080 | 0.110 |
Why?
|
| Adolescent | 1 | 2025 | 6081 | 0.110 |
Why?
|
| Pulmonary Embolism | 2 | 2011 | 38 | 0.100 |
Why?
|
| Endarterectomy | 1 | 2011 | 1 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 17 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2011 | 32 | 0.090 |
Why?
|
| Thrombectomy | 1 | 2011 | 12 | 0.090 |
Why?
|
| Lung Injury | 1 | 2011 | 18 | 0.090 |
Why?
|
| Adult | 2 | 2025 | 13872 | 0.090 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 9 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 23 | 0.070 |
Why?
|
| Heparin | 1 | 2007 | 40 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2007 | 122 | 0.060 |
Why?
|
| Patient Simulation | 1 | 2025 | 14 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2025 | 156 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2024 | 31 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 115 | 0.050 |
Why?
|
| Granulocytes | 1 | 2022 | 26 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 183 | 0.050 |
Why?
|
| Curriculum | 1 | 2025 | 318 | 0.050 |
Why?
|
| Disease Progression | 1 | 2024 | 667 | 0.040 |
Why?
|
| Phenotype | 1 | 2022 | 780 | 0.040 |
Why?
|
| Ampicillin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Dyspnea | 1 | 2019 | 22 | 0.040 |
Why?
|
| Lung | 1 | 2002 | 492 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 94 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2019 | 185 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 1759 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 195 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1285 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 67 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2011 | 55 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 74 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2011 | 91 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 87 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 317 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2011 | 165 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1067 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1124 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 30 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2007 | 162 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1600 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2011 | 1604 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 587 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 375 | 0.010 |
Why?
|
| Animals | 1 | 2002 | 16992 | 0.010 |
Why?
|
| Incidence | 1 | 2007 | 1078 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 863 | 0.010 |
Why?
|